Haemonetics (HAE)

• Market cap: $2.46B
• 1 day: -0.62%
• 5 days: -5.38%
• 1 month: -3.93%
• 3 months: -27.06%
• 6 months: -21.25%
• Year to date: -34.91%
• 1 year: -33.49%
• 5 years: -41.58%
• 10 years: 45.1%
• Sector: Healthcare
• Industry: Medical Devices

About: Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Employees: 3,023

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

283% more call options, than puts

Call options by funds: $22.3M | Put options by funds: $5.82M

24% more repeat investments, than reductions

Existing positions increased: 125 | Existing positions reduced: 101

19% more capital invested

Capital invested by funds: $3.41B [Q1] → $4.04B (+$632M) [Q2]

5.9% more ownership

Funds ownership: 106.92% [Q1] → 112.82% (+5.9%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]

5% less funds holding

Funds holding: 312 [Q1] → 295 (-17) [Q2]

29% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 48

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $62
• Avg. target: $77
• High target: $90

7 analyst ratings

• positive: 6 86%
• neutral: 1 14%
• negative: 0 0%

Raymond James Andrew Cooper	$78	Outperform Downgraded	11 Aug 2025
Barrington Research Michael Petusky	$86	Outperform Maintained	8 Aug 2025
Mizuho Anthony Petrone	$70	Outperform Maintained	8 Aug 2025
JP Morgan Rohin Patel	$62	Neutral Downgraded	8 Aug 2025
Needham Mike Matson	$68	Buy Maintained	7 Aug 2025